Sandy Amorim

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

Sandy Amorim, Anastasios Stathis, Mary Gleeson et al. · The Lancet Haematology · 2016 · 428 citations

Medicine, Pharmacokinetics, Pharmacology +13

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

Anas Younes, Catherine Thiéblemont, Franck Morschhauser et al. · The Lancet Oncology · 2014 · 253 citations

Medicine, Immunology, Oncology +11

Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse

Sophie Bernard, Lauriane Goldwirt, Sandy Amorim et al. · Blood · 2015 · 145 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study

Jehan Dupuis, Franck Morschhauser, Hervé Ghesquières et al. · The Lancet Haematology · 2015 · 108 citations

Medicine, Oncology, Pharmacotherapy +9

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study

Emilio Iannitto, Monica Bellei, Sandy Amorim et al. · British Journal of Haematology · 2018 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +16